Triptorelin embonate: A 6-month formulation for prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 17, 2010, Pages 2929-2932

  Whelan, Peter ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

6 month LH RH; Hormones; Metastatic disease; Prostate cancer

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; TESTOSTERONE; TRIPTORELIN; TRIPTORELIN EMBONATE; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANDROGEN DEFICIENCY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG LEGISLATION; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; ENDOMETRIOSIS; HOT FLUSH; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; METASTASIS; PROSTATE CANCER; REVIEW; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; TESTOSTERONE BLOOD LEVEL; UTERUS MYOMA;

ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PROSTATIC NEOPLASMS; TRIPTORELIN;

EID: 78149444583     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.529900     Document Type: Review

References (15)

1. Schally AV. Aspects of hypothalamic regulation of the pituitary gland. Its implications for the control of reproductive processes. Science 1978;202:18-28
2. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications fr castrate-resistant prostate cancer. Cancer Res 2007;67:5033-41
3. Taylor LG, Cranfield SE, Du XL, et al. Review of major adverse effects f androgen-deprivation therapy in men with prostate cancer. Cancer 2009;115:2388-99
4. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation for the treatment of prostate cancer: consider both benefits and risks. Eur Urol 2009;55:62-75
5. Schally AV. Current concept for improving treatment of prostate cancer on combination of LHRH agonists with other agents. Prog Clin Biol Res 1987;243A:173-97
6. Berthold DR, Pond GR, Soban F, et al. Doctaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-5l
7. Veterans Administration Co-operative Urological Research Group (VACURG-study 1). Carcinoma of the Prostate. Treatment comparisons, J Urol 1967b;98:516-24
8. Studer U.E. Whelan P. Albrecht W. et al. Phase III comparison of early versus delayed endocrine manipulation using LHRH agonist therapy in patients presenting with non-metastatic asymptomatic prostate cancer. J Clin Oncol 2006;24(3):1868-76
9. Calais da Silva FG, Bono A, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results of a randomized phase 3 study f the South European Uro-Oncology Group. Eur Urol 2009;55:1269-77
10. Bolla M., Collette L, Blank L, et al. Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC phase III randomised trial). Lancet 2002;360:103-8
11. DAmico AV, Manola J, Loffredo M, et al. 6 monthly androgen suppression plus radiation versus radiation therap alone for patients with clinically localized prostate cancer. JAMA 2004;292(7):821-7
12. Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prspective randomised study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Therapy for Prostate Cancer. Eur Urol 2000;38:706-13
13. Kim WY, Whang YE, Pruthi RS, et al. Neoadjuvant docetaxel/estramustine prior to radical prostatectomt or external beam radiotherapy in high risk localised prostate cancer: a phase II trial. Urol Oncol 2009. [Epub ahead of print]
14. Schroeder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomised European study. N Eng J Med 2009;360:1320-8
15. Kotwal S, Whelan P. Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer? Scan J Urol Nephrol 2008;42(2):116-20